MedTrace Logo

A Study of HL40626S Tablets in Healthy Adults

NCT07736586 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-08-03

No results posted yet for this study

Summary

This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.

Conditions

  • Psoriasis (PsO)
  • Skin Disease
  • Immune System Disease
  • Skin Diseases, Papulosquamous

Interventions

DRUG

HL40626S tablets

Oral study tablets administered in a dose-escalation design

DRUG

HL40626S placebo

Inactive oral placebo tablets matching the active drug dose-escalation scheme

Sponsors & Collaborators

  • HighsLab Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-02-28
Completion
2027-05-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07736586 on ClinicalTrials.gov